Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2002 Feb;86(2):119–124. doi: 10.1136/adc.86.2.119

Impact of antiretroviral protocols on dynamics of AIDS progression markers

S Resino 1, J Bellon 1, S Sanchez-Ramon 1, D Gurbindo 1, J Ruiz-Contreras 1, J Leon 1, J Ramos 1, M Munoz-Fernandez 1
PMCID: PMC1761061  PMID: 11827906

Abstract

Aims: To assess the "real life" effectiveness of different antiretroviral therapies (ART).

Methods: A retrospective multicentre observational study in 150 HIV-1 vertically infected children on the progression to AIDS (study A), and in 61 HIV-1 infected children on the evolution of the most relevant markers of progression (study B). All children were categorised into four groups: untreated (NT); on monotherapy (MT); on combination therapy (dual-ART); and on potent ART (HAART).

Results: No child in the HAART group progressed to AIDS, whereas 14 children in the NT and seven in the MT groups progressed to AIDS, respectively, the differences being statistically significant. There was a mean increase of 8 units of %CD4+ per year; this was greater in the HAART group than in the other groups. The mean decrease in viral load was 0.65 log10 copies/ml per year; this was greater in the HAART group than in the NT and MT groups. The HAART group had the lowest probability of returning to baseline %CD4+ and viral load.

Conclusion: Potent ART had the greatest protective effect against progression to AIDS in this observational study.

Full Text

The Full Text of this article is available as a PDF (156.7 KB).

Figure 1 .

Figure 1

Open in a new tab

Kaplan–Meier curve of progression to AIDS, classified according to antiretroviral treatment regime.

Figure 2 .

Figure 2

Open in a new tab

Mean CD4+ and CD8+ T lymphocyte percentages in peripheral blood, and plasma log10 VL (copies/ml) in the different groups of HIV-1 infected children. Error bars represent 1 SD.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams D. I., Goldman A. I., Launer C., Korvick J. A., Neaton J. D., Crane L. R., Grodesky M., Wakefield S., Muth K., Kornegay S. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1994 Mar 10;330(10):657–662. doi: 10.1056/NEJM199403103301001. [DOI] [PubMed] [Google Scholar]
  2. Beaulieu P. L., Wernic D., Abraham A., Anderson P. C., Bogri T., Bousquet Y., Croteau G., Guse I., Lamarre D., Liard F. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere. J Med Chem. 1997 Jul 4;40(14):2164–2176. doi: 10.1021/jm9606608. [DOI] [PubMed] [Google Scholar]
  3. Butler K. M., Husson R. N., Balis F. M., Brouwers P., Eddy J., el-Amin D., Gress J., Hawkins M., Jarosinski P., Moss H. Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med. 1991 Jan 17;324(3):137–144. doi: 10.1056/NEJM199101173240301. [DOI] [PubMed] [Google Scholar]
  4. Detels R., Muñoz A., McFarlane G., Kingsley L. A., Margolick J. B., Giorgi J., Schrager L. K., Phair J. P. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998 Nov 4;280(17):1497–1503. doi: 10.1001/jama.280.17.1497. [DOI] [PubMed] [Google Scholar]
  5. Dibbern D. A., Jr, Glazner G. W., Gozes I., Brenneman D. E., Hill J. M. Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor. J Clin Invest. 1997 Jun 15;99(12):2837–2841. doi: 10.1172/JCI119476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Eastman P. S., Shapiro D. E., Coombs R. W., Frenkel L. M., McSherry G. D., Britto P., Herman S. A., Sperling R. S. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis. 1998 Mar;177(3):557–564. doi: 10.1086/514228. [DOI] [PubMed] [Google Scholar]
  7. Froebel K. S., Mok J. Y., Aldhous M. C., Armitage M. P., Arnott M., Reynolds L. M., Peutherer J. F., Burns S. M. In vitro measurement of cytotoxic T cell activity does not predict clinical progression in paediatric HIV disease--two case studies. Clin Exp Immunol. 1997 Oct;110(1):15–21. doi: 10.1046/j.1365-2249.1997.4961393.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Goedert J. J. Vertical transmission of human immunodeficiency virus type 1: insights from studies of multiple pregnancies. Acta Paediatr Suppl. 1997 Jun;421:56–59. doi: 10.1111/j.1651-2227.1997.tb18321.x. [DOI] [PubMed] [Google Scholar]
  9. Gurbindo D., Resino S., Sánchez-Ramón S., León J. A., Muñoz-Fernández M. A. Correlation of viral load and CD8 T-lymphocytes with development of neurological manifestations in vertically HIV-1-infected infants. A prospective longitudinal study. Neuropediatrics. 1999 Aug;30(4):197–204. doi: 10.1055/s-2007-973490. [DOI] [PubMed] [Google Scholar]
  10. Hostetter M. K. Infectious diseases in internationally adopted children: the past five years. Pediatr Infect Dis J. 1998 Jun;17(6):517–518. doi: 10.1097/00006454-199806000-00018. [DOI] [PubMed] [Google Scholar]
  11. Lackritz E. M., Hightower A. W., Zucker J. R., Ruebush T. K., 2nd, Onudi C. O., Steketee R. W., Were J. B., Patrick E., Campbell C. C. Longitudinal evaluation of severely anemic children in Kenya: the effect of transfusion on mortality and hematologic recovery. AIDS. 1997 Oct;11(12):1487–1494. doi: 10.1097/00002030-199712000-00013. [DOI] [PubMed] [Google Scholar]
  12. Lafrenie R. M., Wahl L. M., Epstein J. S., Hewlett I. K., Yamada K. M., Dhawan S. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol. 1996 Feb 15;156(4):1638–1645. [PubMed] [Google Scholar]
  13. Luzuriaga K., Bryson Y., Krogstad P., Robinson J., Stechenberg B., Lamson M., Cort S., Sullivan J. L. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med. 1997 May 8;336(19):1343–1349. doi: 10.1056/NEJM199705083361902. [DOI] [PubMed] [Google Scholar]
  14. McKinney R. E., Jr, Maha M. A., Connor E. M., Feinberg J., Scott G. B., Wulfsohn M., McIntosh K., Borkowsky W., Modlin J. F., Weintrub P. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991 Apr 11;324(15):1018–1025. doi: 10.1056/NEJM199104113241503. [DOI] [PubMed] [Google Scholar]
  15. Mellors J. W., Muñoz A., Giorgi J. V., Margolick J. B., Tassoni C. J., Gupta P., Kingsley L. A., Todd J. A., Saah A. J., Detels R. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997 Jun 15;126(12):946–954. doi: 10.7326/0003-4819-126-12-199706150-00003. [DOI] [PubMed] [Google Scholar]
  16. Mofenson L. M., Korelitz J., Meyer W. A., 3rd, Bethel J., Rich K., Pahwa S., Moye J., Jr, Nugent R., Read J. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis. 1997 May;175(5):1029–1038. doi: 10.1086/516441. [DOI] [PubMed] [Google Scholar]
  17. Muñoz-Fernández M. A., Navarro J., Montes M. G., Cosín J., Zabay J. M., Fernández-Cruz E. Quantification of low levels of human immunodeficiency virus (HIV) type 1 RNA in P24 antigen-negative, asymptomatic, HIV-positive patients by PCR. J Clin Microbiol. 1996 Feb;34(2):404–408. doi: 10.1128/jcm.34.2.404-408.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Muñoz-Fernández M. A., Obregón E., Navarro J., Börner C., Gurbindo M. D., Sampelayo T. H., Fernández-Cruz E. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatr Res. 1996 Oct;40(4):597–602. doi: 10.1203/00006450-199610000-00014. [DOI] [PubMed] [Google Scholar]
  19. O'Brien W. A., Hartigan P. M., Daar E. S., Simberkoff M. S., Hamilton J. D. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med. 1997 Jun 15;126(12):939–945. doi: 10.7326/0003-4819-126-12-199706150-00002. [DOI] [PubMed] [Google Scholar]
  20. Pizzo P. A., Eddy J., Falloon J., Balis F. M., Murphy R. F., Moss H., Wolters P., Brouwers P., Jarosinski P., Rubin M. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988 Oct 6;319(14):889–896. doi: 10.1056/NEJM198810063191401. [DOI] [PubMed] [Google Scholar]
  21. Resino S., Gurbindo D., Cano J. M., Sanchez-Ramón S., Muõz-Fernández M. A. Predictive markers of clinical outcome in vertically HIV-1-infected infants. A prospective longitudinal study. Pediatr Res. 2000 Apr;47(4 Pt 1):509–515. doi: 10.1203/00006450-200004000-00016. [DOI] [PubMed] [Google Scholar]
  22. Sacristán J. A., Soto J., Galende I. Evaluación crítica de ensayos clínicos. Med Clin (Barc) 1993 May 22;100(20):780–787. [PubMed] [Google Scholar]
  23. Sharfstein J., Wise P. H. Inadequate hepatitis B vaccination of adolescents and adults at an urban community health center. J Natl Med Assoc. 1997 Feb;89(2):86–92. [PMC free article] [PubMed] [Google Scholar]
  24. de Martino M., Veneruso G., Gabiano C., Frongia G., Tulisso S., Lombardi E., Tovo P. A., Galli L., Vierucci A. Airway resistance and spirometry in children with perinatally acquired human immunodeficiency virus-type 1 infection. Pediatr Pulmonol. 1997 Dec;24(6):406–414. doi: 10.1002/(sici)1099-0496(199712)24:6<406::aid-ppul5>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES